Black Diamond Therapeutics, Inc.
BDTXBlack Diamond Therapeutics is a clinical-stage oncology company focused on developing MasterKey therapies that target families of oncogenic mutations.
$99.13M-38.2%
Table of contents
Earnings
Next report
Aug 6, 2026 (In 1 week)EPS estimate-$0.18
Competitors
By market cap
By revenue growth
Profile
Black Diamond Therapeutics is a clinical-stage oncology company focused on developing MasterKey therapies that target families of oncogenic mutations. The company utilizes its proprietary Mutation-Allostery-Pharmacology (MAP) drug discovery engine to design brain-penetrant, small molecule inhibitors that address genetically defined tumors while sparing healthy wild-type proteins.
Competitive position
A clinical-stage innovator utilizing a proprietary MAP engine to target broad mutation families rather than single-site mutations.
GeographiesUnited States
Customer segmentsPatients with genetically defined cancers, Healthcare providers, Pharmaceutical partners
Business modelR&D intensive, Licensing and royalties
SuppliersGenetic sequencing providers, Contract research organizations (CROs), Raw material suppliers for medicinal chemistry
CustomersOncology clinics, Specialty pharmacies, Larger pharmaceutical companies for potential commercialization
CountryUnited States of America
Listed2020
Employees54.0
CEOMark A. Velleca
SectorHealthcare
IndustryBiotechnology
Websiteblackdiamondtherapeutics.com
FilingsSEC EDGAR
Questions, answered.
- What is Black Diamond Therapeutics, Inc.'s market cap?
- Black Diamond Therapeutics, Inc. (BDTX) has a market capitalization of $99.1M and trades on NASDAQ.
- Who are Black Diamond Therapeutics, Inc.'s competitors?
- Black Diamond Therapeutics, Inc.'s key competitors include Silexion Therapeutics Corp Ordinary Shares, Prelude Therapeutics Incorporated, OnKure Therapeutics, Inc. Class A Common Stock, and others. These companies compete in similar markets and product categories.
- Where is Black Diamond Therapeutics, Inc. headquartered?
- Black Diamond Therapeutics, Inc. is headquartered in United States of America and employs approximately 54 people. It has been publicly traded since 2020.